Study of HR20013 for Injection in Patients With Malignant Solid Tumors
Status:
Not yet recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
To evaluate the safety and pharmacokinetics of single-dose HR20013 for injection combined
with dexamethasone in patients with malignant solid tumors receiving cisplatin-based
chemotherapy.